TAVR-related TP is predictable and classification by PTP and TP severity prior to TAVR allows for better risk stratification in predicting in-hospital clinical outcomes. Major TP in the presence of worsening TP is predictable and is associated with worse clinical outcomes. © 2014 Wiley Periodicals, Inc.

S econd-generation metallic drug-eluting stents (DES) have been widely recommended for percutaneous coronary intervention.1 One of the main drawbacks of these devices is the risk of late adverse events (ie, beyond 1 year), particularly repeat revascularization, which are partly related to the persistence of the metallic stents in the coronary artery wall.2 In this context, the bioresorbable vascular scaffolds (BVS) have emerged as an attractive breakthrough technology. These scaffolds offer the mechanical support similar to DES followed by complete resolution within 3 to 4 years, thus, maintaining the coronary vasomotion, which is reduced with DES and has been linked to the increased risk of repeat revascularization. 3 Preclinical studies with BVS had shown that these devices improve vessel remodeling once resolved. 4 The Absorb™ (Abbott Vascular, Abbott Park, IL) BVS has been the widely commercially available among the different BVS in development. The US Food and Drug Administration recently approved the Absorb™ BVS 5 ; Absorb™ this was based on the results of the 1-year data from the largest randomized trial to date (ie, ABSORB III trial [A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With De Novo Native Coronary Artery Lesions]) evaluating clinical outcomes with the Absorb™ BVS and demonstrated the noninferiority of BVS compared with everolimus-eluting stents (EES) at 1 year. 6 Data from meta-analyses suggested that BVS might be associated Background-Data regarding the long-term efficacy and safety of everolimus-eluting bioresorbable vascular scaffolds (BVS) compared with everolimus-eluting stents are limited. This meta-analysis aimed to compare the long-term outcomes with both devices. Methods and Results-Randomized trials reporting clinical outcomes beyond 1 year and comparing BVS with everolimuseluting stents were included. Summary estimates risk ratios (RRs) were constructed. The primary efficacy outcome was target lesion failure, defined as cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization, and the primary safety outcome was definite or probable stent/scaffold thrombosis. Six trials with 5392 patients were included (mean follow-up, 25 months). BVS had a higher rate of target lesion failure (RR, 1.33; 95% confidence interval [CI], 1.11-1.58) driven by the higher rates of target vessel myocardial infarction (RR, 1.65; 95% CI, 1.26-2.17) and target lesion revascularization (RR, 1.39; 95% CI, 1.08-1.78). The risk of definite or probable stent/ scaffold thrombosis (RR, 3.22; 95% CI, 1.89-5.49) and very late stent/scaffold thrombosis (>1 year; RR, 4.78; 95% CI, 1.66-13.8) was higher with BVS. The risk of cardiac and all-cause mortality was similar in both groups. Conclusions-Compared with everolimus-eluting stents, BVS is associated with increased risk of target lesion failuredriven by the increased rates of target vessel myocardial infarction and ischemia-driven target lesion ...

Cytometric studies utilizing flow cytometry or multi-well culture plate fluorometry are often limited by a deficit in temporal resolution and a lack of single cell consideration. Unfortunately, many cellular processes, including signaling, motility, and molecular transport, occur transiently over relatively short periods of time and at different magnitudes between cells. Here we demonstrate the multitrap nanophysiometer (MTNP), a low-volume microfluidic platform housing an array of cell traps, as an effective tool that can be used to study individual unattached cells over time with precise control over the intercellular microenvironment. We show how the MTNP platform can be used for hematologic cancer cell characterization by measuring single T cell levels of CRAC channel modulation, non-translational motility, and ABC-transporter inhibition via a calcein-AM efflux assay. The transporter data indicate that Jurkat T cells exposed to indomethacin continue to accumulate fluorescent calcein for over 60 minutes after calcein-AM is removed from the extracellular space.